Browsing by Subject "p62/SQSTM1"

Glioblastoma Multiforme (GBM) is the most common and aggressive types of glioma in adults. Autophagy allows degradation and recycling of cellular components such as damaged proteins and dysfunctional organelles to sustain the metabolism and homeostasis of rapidly growing cells. Recent reports suggest that autophagy may promote tumor cell survival under stress conditions and can be an emerging target for cancer therapy. Autophagy inhibitor combined with TMZ can induce glioblastoma cell death and improve the radiotherapy efficacy. The Neuropilin-1 (NRP1) is 120 kDa-130 kDa type I integral transmembrane protein. It was originally identified as a co-receptor for the class 3 semaphorins (SEMA3) involved in axon guidance and found to interact with VEGF/VEGFR2 to promote angio-genesis. Recent studies have revealed its much broader roles on tumor progression. In various types of human cancers, NRP1 is often up-regulated and associated with aggressive clinical tumor behaviour. NRP1 overexpression is independently correlated with poor prognosis in human glioma and contributes to balance the glioblastoma cell proliferation and survival. In cancer cells, it interacts with diverse growth factor receptors including TGFR, c-Met, FGFR, EGFR as well as PDGFR to promote their signal-ling pathways in tumor cell survival, proliferation, migration and invasion. Although these functions of NRP1 mainly rely on its ectodomain, the cytoplasmic domain of NRP1 has been recently found to be essential for the internalization of NRP1-binding complex. In addition, the C-terminal SEA sequence on its cytoplasmic domain have potential to bind intracellular PDZ domain-containing molecules. Tyrosine phosphorylation of p130Cas has been identified to regulate the downstream pathways of NRP1, which is dependent on NRP1 intracellular domain. However, the downstream trafficking of NRP1 is poorly understood and its tumor-promoting function relevance remains ambiguous. The p62/Sequestosome 1, encoded by SQSTM1 gene, is an intracellular protein commonly found in inclusion bodies. It is asso-iated with protein aggregation diseases in liver and brain. Owing to its ability to interact with multiple important cellular intermediates, it works as a 'hub' adaptor linked to nuclear factor-kappaB (NF-κB) activation, protein aggregates formation, selective autophagy, adipogenesis and tumorigenesis. The p62 has a critical role on autophagy via regulating the collection and delivery of ubiquitinylated cargos to the autophagosome via its PB1, UBA and LIR domains. On the other hand, recent study has revealed a new role of p62 as a negative regulator in the autophagy regulation. High level of p62 is able to suppress the autophagy by pro-moting mTORC1 activation. This route forms a feed-forward loop for increasing level of p62 due to the reduced autophagy. Thus, p62 plays a critical role in regulation of autophagy. Here we observed that suppression of NRP1 in glioblastoma cell clearly exhibits a defected autophagy accompanied by marked accumulation of p62, the autophagic adaptor. Overexpression of NRP1 by glioblastoma cells shows enhanced autophagy flux. These data suggests the role of NRP1 in autophagy promotion. In addition, we mapped out that p62 binds to the cytoplasmic domain of NRP1 mediating its pro-autophagy effects. PB1 domain of p62 overexpression enhances the p62-positive aggregates and NRP1/p62 interaction. Taken together, our results define a novel role of NRP1 in the regulation of autophagy through its association with p62. In summary, our present results provide novel insights into the molecular basis of the emerging interplay between NRP1 and autophagy, the identification of a new cytoplasmic protein that binding to intracellular domain of NRP1 and the implications of the p62-mediated signalling loop for NRP1-promoted autophagy in GBMs. Since efforts to inhibit autophagy to improve GBM therapy have thereby attracted great interest, our findings may provide valuable clues for future cancer therapeutic strategies.